Faculty of 1000 evaluation for ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design.

De Novo ◽

Controlled Trial ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Randomized Controlled ◽

Stent System ◽

Vascular Scaffold ◽

And Performance

Faculty Opinions recommendation of ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964511.793468451 ◽

2013 ◽

Author(s):

Mauricio Cohen

Keyword(s):

De Novo ◽

Controlled Trial ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Randomized Controlled ◽

Stent System ◽

Vascular Scaffold ◽

And Performance

Faculty Opinions recommendation of ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717964511.793467373 ◽

2012 ◽

Author(s):

Michael Haney

Keyword(s):

De Novo ◽

Controlled Trial ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Randomized Controlled ◽

Stent System ◽

Vascular Scaffold ◽

And Performance

TCT-312 4-year Clinical Results of a Randomized trial Evaluating the Absorb Bioresorbable Vascular Scaffold vs. Metallic Drug-eluting Stent in de novo Native Coronary Artery Lesions: Data from the ABSORB Japan Trial

10.1016/j.jacc.2018.08.1453 ◽

2018 ◽

Vol 72 (13) ◽

pp. B128-B129

Author(s):

Kengo Tanabe ◽

Ken Kozuma ◽

Takeshi Kimura

Keyword(s):

Coronary Artery ◽

Randomized Trial ◽

De Novo ◽

Clinical Results ◽

Drug Eluting Stent ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Vascular Scaffold ◽

Drug Eluting

TCT-592 Lower Five Year Event Rates In The Genous Endothelial Progenitor Cell Capturing Stent Compared With A Drug Eluting Stent In De-novo Coronary Artery Lesions With A High-risk Of Restenosis; A Randomized Controlled Trial

10.1016/j.jacc.2014.07.656 ◽

2014 ◽

Vol 64 (11) ◽

pp. B172-B173

Author(s):

Pier Woudstra ◽

Marcel A. Beijk ◽

Karel T. Koch ◽

Jan Baan ◽

Marije M. Vis ◽

...

Keyword(s):

Coronary Artery ◽

Progenitor Cell ◽

De Novo ◽

Controlled Trial ◽

Drug Eluting Stent ◽

Coronary Artery Lesions ◽

Randomized Controlled ◽

Drug Eluting ◽

Event Rates

TCT-165 5-Year Clinical Results of a Randomized Trial Evaluating the Absorb Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in De Novo Native Coronary Artery Lesions: Data From the ABSORB Japan Trial

10.1016/j.jacc.2019.08.220 ◽

2019 ◽

Vol 74 (13) ◽

pp. B164

Author(s):

Ken Kozuma ◽

Takeshi Kimura ◽

Kengo Tanabe

Keyword(s):

Coronary Artery ◽

Randomized Trial ◽

De Novo ◽

Clinical Results ◽

Drug Eluting Stent ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Vascular Scaffold ◽

Drug Eluting

First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial

EuroIntervention ◽

10.4244/eij-d-17-00306 ◽

2017 ◽

Vol 13 (4) ◽

pp. 415-423 ◽

Cited By ~ 17

Author(s):

Ashok Seth ◽

Yoshinobu Onuma ◽

Ricardo Costa ◽

Praveen Chandra ◽

Vinay K. Bahl ◽

...

Keyword(s):

Coronary Artery ◽

De Novo ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Human Evaluation ◽

Vascular Scaffold

FIRST REPORT OF THE THREE YEAR CLINICAL AND MULTI–MODALITY IMAGING RESULTS OF THE ABSORB TRIAL EVALUATING THE ABSORB EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

10.1016/s0735-1097(13)61731-3 ◽

2013 ◽

Vol 61 (10) ◽

pp. E1731 ◽

Cited By ~ 5

Author(s):

Patrick Serruys

Keyword(s):

Coronary Artery ◽

De Novo ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

First Report ◽

Imaging Results ◽

Vascular Scaffold

Sirolimus- vs Paclitaxel-Eluting Stents in De Novo Coronary Artery Lesions: The REALITY Trial: A Randomized Controlled Trial

Yearbook of Medicine ◽

10.1016/s0084-3873(08)70218-9 ◽

2007 ◽

Vol 2007 ◽

pp. 344-347

Author(s):

W.H. Frishman

Keyword(s):

Coronary Artery ◽

De Novo ◽

Controlled Trial ◽

Coronary Artery Lesions ◽

Randomized Controlled

TCT-35 Evaluation of the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold (Absorb BVS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions: 3 Year Clinical Results of the ABSORB Cohort B1 Trial

10.1016/j.jacc.2012.08.043 ◽

2012 ◽

Vol 60 (17) ◽

pp. B11 ◽

Cited By ~ 1

Author(s):

Peter Smits

Keyword(s):

Coronary Artery ◽

De Novo ◽

Clinical Results ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Vascular Scaffold ◽

Absorb Bvs

EVALUATION OF THE ABSORB EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD (ABSORB BVS) IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS: 2 YEAR CLINICAL RESULTS OF ABSORB COHORT B TRIAL

10.1016/s0735-1097(12)60320-9 ◽

2012 ◽

Vol 59 (13) ◽

pp. E319 ◽

Cited By ~ 3

Author(s):

Dariusz Dudek

Keyword(s):

Coronary Artery ◽

De Novo ◽

Clinical Results ◽

Coronary Artery Lesions ◽

Native Coronary Artery ◽

Vascular Scaffold ◽

Absorb Bvs